• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 488082 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416819360 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416819360 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulating Shares of Amarin on 1.6x Above-Average Volume (AMRN)

Published on Fri, 04/26/2013 - 13:16
By Peter Chu

Amarin shares are trading on heavy volume today, having risen 5.9% to $6.77. Approximately 5.4 million shares have changed hands today vs. average 30-day volume of 3.4 million shares. Unusually high volume can signify a potential turning point or validate a breakout.

In the past 52 weeks, shares of Amarin have traded between a low of $6.34 and a high of $15.96 and are now at $6.77, which is 7% above that low price. The 200-day and 50-day moving averages have moved 1.22% lower and 1.41% lower over the past week, respectively.

Amarin (NASDAQ:AMRN) has potential upside of 125.8% based on a current price of $6.77 and analysts' consensus price target of $15.29. The stock should find initial resistance at its 50-day moving average (MA) of $7.78 and further resistance at its 200-day MA of $10.48.

Amarin Corporation PLC is a clinical-stage biopharmaceutical company. The Company researches, develops, and commercializes drugs for the treatment of hypertriglyceridemia, central nervous system disorders, and cardiovascular diseases.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Post Earnings Update: International Pape...

When International Paper (NYSE:IP) reported earnings two weeks ago on November 4th, 201 ...

Protective Life Earnings Review: 19 Days...

Two weeks ago on November 3rd, 2014 Protective Life (NYSE:PL) reported earnings and ana ...

Earnings Look Back: Estee Lauder Is Up 1...

18 days ago, on November 4th, 2014, Estee Lauder (NYSE:EL) reported its earnings. Anal ...

Delek US Holdings Earnings Review: 17 Da...

When Delek US Holdings (NYSE:DK) reported earnings two weeks ago on November 5th, 2014, ...

Earnings Look Back: Stifel Financial Is ...

When Stifel Financial (NYSE:SF) reported earnings two weeks ago on November 6th, 2014, ...

Post Earnings Update: Dean Foods Has Cli...

A week ago on November 10th, 2014 Dean Foods (NYSE:DF) reported earnings and analysts, ...

Earnings Look Back: CF Industries Is Up ...

When CF Industries (NYSE:CF) reported earnings two weeks ago on November 5th, 2014, ana ...

Spectra Energy Earnings Hindsight: Up 0....

When Spectra Energy (NYSE:SE) reported earnings 17 days ago on November 5th, 2014, anal ...